



5 August 2005

The Manager  
Company Announcements  
Australian Stock Exchange  
4<sup>th</sup> Floor  
20 Bridge Street  
SYDNEY NSW 2000  
Dear Sir,

### **Resonance Health to Provide Expanded FerriScan® Service to Major Pharmaceutical Company**

Perth, Western Australia, 5 August 2005. Resonance Health (ASX:RHT) today announced the signing of a Frame Agreement between its operating subsidiary, Resonance Health Analysis Services Pty Ltd (formerly Inner Vision Biometrics) and Novartis Pharma AG, a Swiss Pharmaceutical company. Earlier last year, a similar agreement was signed with Novartis Pharmaceuticals Corporation, (New Jersey, US).


Under this agreement, the Resonance Health Group will provide its FerriScan® diagnostic test in connection with clinical studies being undertaken by Novartis Pharma AG. The initial scope of activities is anticipated to generate approximately US\$300,000 revenue for the Resonance Health Group through to the end of 2007, and dependent on Novartis' progress with the trials.

FerriScan® is used in the diagnosis and management of iron overload, in disease states such as thalassemia and hemochromatosis. Iron overload is also found in other disease states such as sickle cell anaemia and a variety of chronic liver diseases.

#### **About Resonance Health Ltd**

Resonance Health Limited, through its wholly owned subsidiary Resonance Health Analysis Services (RHAS), continues to commercialise FerriScan, a non-invasive diagnostic test to measure the iron content of a patient's liver to assist clinicians in the detection and treatment of iron overload disorders such as hereditary haemochromatosis and thalassemia.

Traditional methods for diagnosing iron overload in the liver involve use of indirect blood markers and the removal of a biopsy sample from the liver. Neither of these tools are optimal for measurement of iron levels. Biopsies are invasive and dangerous, whilst both methods are inaccurate due to sample size or the indirect nature of the test.



FerriScan uses existing Magnetic Resonance Imaging (MRI) machines at radiology facilities worldwide to provide suitable scan images of the liver. The images are subsequently analysed at a centralised RHAS image analysis centre to quantify iron loading using proprietary software. The FerriScan test provides a safe and accurate alternative to traditional diagnostic methods.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, U.K and Europe. Further information about Resonance Health and FerriScan can be obtained from the following web sites: [www.resonancehealth.com](http://www.resonancehealth.com) and [www.ferriscan.com](http://www.ferriscan.com)

<b>Media and Investor Relations</b>	<b>Resonance Health</b>
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: <a href="mailto:rpiercy@bcg.com.au">rpiercy@bcg.com.au</a>	Dr James Williams Managing Director Resonance Health Limited T - +61 9286 5300 M - 0409 050 519 Email: <a href="mailto:jamesw@ferriscan.com">jamesw@ferriscan.com</a>